Viyash Scientific Limited (NSE:SEQUENT) — Market Cap & Net Worth
Market Cap & Net Worth: Viyash Scientific Limited (SEQUENT)
Viyash Scientific Limited (NSE:SEQUENT) has a market capitalization of $529.07 Million (Rs48.92 Billion) as of July 8, 2026. Listed on the NSE stock exchange, this India-based company holds position #11999 globally and #594 in its home market, demonstrating a 0.60% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Viyash Scientific Limited's stock price Rs193.72 by its total outstanding shares 252537098 (252.54 Million). See SEQUENT capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Viyash Scientific Limited Market Cap History: 2016 to 2026
Viyash Scientific Limited's market capitalization history from 2016 to 2026. Data shows growth from $298.04 Million to $529.07 Million (0.84% CAGR).
Index Memberships
Viyash Scientific Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY MICROCAP 250
NIFTYMICROCAP250
|
$152.53 Billion | 0.35% | #101 of 250 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.24 Trillion | 0.02% | #461 of 750 |
Weight: Viyash Scientific Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Viyash Scientific Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Viyash Scientific Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.04x
Viyash Scientific Limited's market cap is 0.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.60x
Viyash Scientific Limited's market cap is 2.60 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $298.04 Million | $6.01 Billion | -$184.69 Million | 0.05x | N/A |
| 2017 | $265.22 Million | $6.78 Billion | -$138.24 Million | 0.04x | N/A |
| 2018 | $184.10 Million | $8.42 Billion | $4.22 Billion | 0.02x | 0.04x |
| 2019 | $192.68 Million | $10.22 Billion | $486.60 Million | 0.02x | 0.40x |
| 2020 | $462.05 Million | $11.61 Billion | $699.05 Million | 0.04x | 0.66x |
| 2021 | $439.43 Million | $13.52 Billion | $954.42 Million | 0.03x | 0.46x |
| 2022 | $239.24 Million | $14.10 Billion | $409.55 Million | 0.02x | 0.58x |
| 2023 | $310.66 Million | $14.18 Billion | -$1.21 Billion | 0.02x | N/A |
| 2024 | $480.29 Million | $13.66 Billion | -$358.69 Million | 0.04x | N/A |
| 2025 | $569.54 Million | $15.51 Billion | $218.80 Million | 0.04x | 2.60x |
Competitor Companies of SEQUENT by Market Capitalization
Companies near Viyash Scientific Limited in the global market cap rankings as of July 8, 2026.
Key companies related to Viyash Scientific Limited by market ranking:
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #504 globally with a market cap of $52.99 Billion USD ( CN¥362.14 Billion CNY).
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #552 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #629 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #504 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $52.99 Billion | CN¥56.77 |
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #552 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $44.28 |
| #629 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.80 |
Viyash Scientific Limited Historical Marketcap From 2016 to 2026
Between 2016 and today, Viyash Scientific Limited's market cap moved from $298.04 Million to $ 529.07 Million, with a yearly change of 0.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs529.07 Million | -7.11% |
| 2025 | Rs569.54 Million | +18.58% |
| 2024 | Rs480.29 Million | +54.60% |
| 2023 | Rs310.66 Million | +29.85% |
| 2022 | Rs239.24 Million | -45.56% |
| 2021 | Rs439.43 Million | -4.89% |
| 2020 | Rs462.05 Million | +139.80% |
| 2019 | Rs192.68 Million | +4.66% |
| 2018 | Rs184.10 Million | -30.58% |
| 2017 | Rs265.22 Million | -11.01% |
| 2016 | Rs298.04 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 7th, 2026 the market cap of Viyash Scientific Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $529.07 Million USD |
| MoneyControl | $529.07 Million USD |
| MarketWatch | $529.07 Million USD |
| marketcap.company | $529.07 Million USD |
| Reuters | $529.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Viyash Scientific Limited
Viyash Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides finished dosage formulation in therapeutic areas, such as nutrition, pain management, parasite control, antibiotics, and gut health for livestock, poultry, and companion animals. It also offers analytical services; and VET formulation services. The company was former… Read more